JP5460797B1 - アミド誘導体及び安定性指標としてのその使用 - Google Patents

アミド誘導体及び安定性指標としてのその使用 Download PDF

Info

Publication number
JP5460797B1
JP5460797B1 JP2012202696A JP2012202696A JP5460797B1 JP 5460797 B1 JP5460797 B1 JP 5460797B1 JP 2012202696 A JP2012202696 A JP 2012202696A JP 2012202696 A JP2012202696 A JP 2012202696A JP 5460797 B1 JP5460797 B1 JP 5460797B1
Authority
JP
Japan
Prior art keywords
luliconazole
amide
formulation
preparation
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012202696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014058449A (ja
Inventor
孝明 増田
博志 山口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012202696A priority Critical patent/JP5460797B1/ja
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to RU2015113587A priority patent/RU2612557C2/ru
Priority to IN2930DEN2015 priority patent/IN2015DN02930A/en
Priority to CN201380047770.5A priority patent/CN104662017A/zh
Priority to PCT/JP2013/055025 priority patent/WO2014041825A1/en
Priority to US14/347,939 priority patent/US9145401B2/en
Priority to EP13709572.5A priority patent/EP2895480A1/en
Application granted granted Critical
Publication of JP5460797B1 publication Critical patent/JP5460797B1/ja
Publication of JP2014058449A publication Critical patent/JP2014058449A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2012202696A 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用 Active JP5460797B1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2012202696A JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用
IN2930DEN2015 IN2015DN02930A (enExample) 2012-09-14 2013-02-19
CN201380047770.5A CN104662017A (zh) 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途
PCT/JP2013/055025 WO2014041825A1 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation
RU2015113587A RU2612557C2 (ru) 2012-09-14 2013-02-19 Амидное производное и его применение в качестве критерия стабильности фармацевтической композиции луликоназола
US14/347,939 US9145401B2 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation
EP13709572.5A EP2895480A1 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012202696A JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用

Publications (2)

Publication Number Publication Date
JP5460797B1 true JP5460797B1 (ja) 2014-04-02
JP2014058449A JP2014058449A (ja) 2014-04-03

Family

ID=47884458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012202696A Active JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用

Country Status (7)

Country Link
US (1) US9145401B2 (enExample)
EP (1) EP2895480A1 (enExample)
JP (1) JP5460797B1 (enExample)
CN (1) CN104662017A (enExample)
IN (1) IN2015DN02930A (enExample)
RU (1) RU2612557C2 (enExample)
WO (1) WO2014041825A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2015113341A (ja) * 2014-03-26 2015-06-22 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416758B8 (en) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5635075B2 (ja) 2009-08-25 2014-12-03 株式会社ポーラファルマ 抗真菌医薬組成物
EP2579847A1 (en) 2010-06-11 2013-04-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN104284662A (zh) 2012-09-14 2015-01-14 宝丽制药股份有限公司 晶体及包含该晶体的药物制剂
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
CN104619703A (zh) 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP3230280A4 (en) * 2014-12-12 2018-05-09 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
JP7259873B2 (ja) * 2019-02-07 2023-04-18 株式会社島津製作所 分析方法、分析装置およびプログラム

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
DE19681478B4 (de) 1995-07-08 2006-09-21 Nihon Nohyaku Co., Ltd. R-(-)-(E)-[4-(2,4-Dichlorphenyl)-1,3-dithiolan-2-yliden]-1-imidazolylacetonitril,Verfahren zu seiner Herstellung und seine Verwendung
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
JP5184342B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
US8268876B2 (en) 2006-03-08 2012-09-18 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
BRPI0621446C1 (pt) 2006-03-08 2021-05-25 Nihon Nohyaku Co Ltd composição farmacêutica para uso externo
WO2009031643A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 抗真菌組成物
EP2191826B1 (en) 2007-09-05 2017-03-08 Pola Pharma Inc. Pharmaceutical composition
EP2191828B1 (en) 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
JP5654497B2 (ja) * 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ，インコーポレイテッド 抗真菌製剤
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2416758B8 (en) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5635075B2 (ja) 2009-08-25 2014-12-03 株式会社ポーラファルマ 抗真菌医薬組成物
EP2579847A1 (en) * 2010-06-11 2013-04-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
RU2621615C2 (ru) 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
CN104284662A (zh) 2012-09-14 2015-01-14 宝丽制药股份有限公司 晶体及包含该晶体的药物制剂
CN104619703A (zh) 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2015113341A (ja) * 2014-03-26 2015-06-22 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Also Published As

Publication number Publication date
IN2015DN02930A (enExample) 2015-09-18
WO2014041825A1 (en) 2014-03-20
CN104662017A (zh) 2015-05-27
RU2015113587A (ru) 2016-11-10
US9145401B2 (en) 2015-09-29
US20150191456A1 (en) 2015-07-09
EP2895480A1 (en) 2015-07-22
JP2014058449A (ja) 2014-04-03
RU2612557C2 (ru) 2017-03-09

Similar Documents

Publication Publication Date Title
JP5460797B1 (ja) アミド誘導体及び安定性指標としてのその使用
JP5686874B2 (ja) 医薬組成物
JP5160409B2 (ja) 外用の医薬組成物
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
KR101754697B1 (ko) 항진균성 약제학적 조성물
US20080139558A1 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
JP5587488B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
EP2005959A1 (en) External pharmaceutical composition
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5926756B2 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP2015113343A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP4965428B2 (ja) セミカルバジド誘導体を含むフリーラジカル消去剤
KR101981482B1 (ko) 에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물
JP2015027983A (ja) 結晶及び該結晶を含有してなる医薬製剤
JP3805900B2 (ja) 抗真菌剤及びそれを含有する組成物
JPWO2007052794A1 (ja) オルト置換アニリン誘導体及び抗酸化薬
JP2000034287A (ja) 抗真菌剤
JP2000053620A (ja) 芳香族抗真菌剤
JP2000053619A (ja) 芳香族抗真菌剤
JP2016515605A (ja) 抗アレルギー活性を有する新規なカルコン誘導体類

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140114

R150 Certificate of patent or registration of utility model

Ref document number: 5460797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250